Detalhe da pesquisa
1.
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Ann Hematol
; 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443660
2.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167024
3.
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Blood
; 134(7): 641-644, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31243043
4.
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Ann Hematol
; 100(4): 987-993, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495922
5.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Br J Haematol
; 184(4): 558-569, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506764
6.
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharm Res
; 36(7): 93, 2019 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044267
7.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24401022
8.
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Blood
; 126(18): 2110-7, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26316624
9.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Haematologica
; 102(10): 1796-1805, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751558
10.
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Hematol Oncol
; 35(4): 671-678, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27878835
11.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol
; 17(2): 200-211, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26655421
12.
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Br J Haematol
; 175(3): 462-466, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27611233
13.
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
Blood
; 124(14): 2196-202, 2014 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25143487
14.
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
Am J Hematol
; 96(9): E353-E356, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152612
15.
Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.
Biol Blood Marrow Transplant
; 21(5): 860-5, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25617807
16.
Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.
Am J Hematol
; 90(6): 511-4, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25752923
17.
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
Br J Haematol
; 186(1): 175-180, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739324
18.
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Am J Hematol
; 94(7): E183-E185, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30945328
19.
Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion.
J Leukoc Biol
; 113(3): 305-314, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807447
20.
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
Ann Biol Clin (Paris)
; 81(4): 379-387, 2023 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864443